1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Benign Prostatic Hyperplasia Treatment Market
2.3. Global Benign Prostatic Hyperplasia Treatment Market, By Treatment, 2025 (US$ Million)
2.4. Global Benign Prostatic Hyperplasia Treatment Market, By End-user, 2025 (US$ Million)
2.5. Global Benign Prostatic Hyperplasia Treatment Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025

3. Benign Prostatic Hyperplasia Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Benign Prostatic Hyperplasia Treatment Market Vendors
3.2. Strategies Adopted by Benign Prostatic Hyperplasia Treatment Market Vendors

4. Benign Prostatic Hyperplasia Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Benign Prostatic Hyperplasia Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Drug Class
5.3.1.1. Alpha-blockers
5.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
5.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
5.3.1.4. Others
5.3.2. Minimally Invasive Surgeries
5.3.2.1. Transurethral Resection of the Prostate (TURP)
5.3.2.2. Transurethral Incision of the Prostate (TUIP)
5.3.2.3. Robotic Surgeries
5.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
5.3.2.5. Prostatic Urethral Lift
5.3.2.6. Others
5.3.3. Laser Therapy
5.3.4. Others

6. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Specialty Clinics
6.3.4. Others

7. North America Benign Prostatic Hyperplasia Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
7.4. Benign Prostatic Hyperplasia Treatment Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.4.1.1.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.4.1.2.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.4.1.3.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)

8. UK and European Union Benign Prostatic Hyperplasia Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
8.4. Benign Prostatic Hyperplasia Treatment Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.4.1.1.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.4.1.2.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.4.1.3.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.4.1.4.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.4.1.5.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.4.1.6.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)

9. Asia Pacific Benign Prostatic Hyperplasia Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
9.4. Benign Prostatic Hyperplasia Treatment Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.4.1.1.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.4.1.2.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.4.1.3.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.4.1.4.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.4.1.5.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.4.1.6.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)

10. Latin America Benign Prostatic Hyperplasia Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
10.4. Benign Prostatic Hyperplasia Treatment Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.4.1.1.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.4.1.2.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.4.1.3.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)

11. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
11.3. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
11.4. Benign Prostatic Hyperplasia Treatment Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
11.4.1.1.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
11.4.1.2.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Benign Prostatic Hyperplasia Treatment Market: By Treatment, 2024-2034, USD (Million)
11.4.1.3.2. Benign Prostatic Hyperplasia Treatment Market: By End-user, 2024-2034, USD (Million)

12. Company Profile
12.1. Boston Scientific Corporation (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Teleflex Incorporated
12.3. Endo International plc
12.4. Urologix, LLC
12.5. LISA Laser
12.6. Olympus Corporation